Michael S. Sherman, MD, MBA

With pharmacy costs increasing so quickly, there is increasing pressure for P&T and Technology Assessment Committees to consider the value as well as the clinical efficacy of the drugs under evaluation. By providing an objective framework for assessing value, RxScorecard fills a gap in the existing toolkit available to health plans. And with greater discussion around narrower formularies, RxScorecard becomes even more important.